Silencing or Fueling Metastasis with VEGF Inhibitors: Antiangiogenesis Revisited

被引:325
作者
Loges, Sonja [1 ,2 ]
Mazzone, Massimiliano [1 ,2 ]
Hohensinner, Philipp [1 ,2 ]
Carmeliet, Peter [1 ,2 ]
机构
[1] VIB, Vesalius Res Ctr, B-3000 Louvain, Belgium
[2] Katholieke Univ Leuven, Vesalius Res Ctr, B-3000 Louvain, Belgium
关键词
ENDOTHELIAL GROWTH-FACTOR; PACLITAXEL PLUS BEVACIZUMAB; TUMOR VASCULATURE; CANCER; RECEPTOR; ANGIOGENESIS; CHEMOTHERAPY; PROGRESSION; IRINOTECAN; EFFICACY;
D O I
10.1016/j.ccr.2009.02.007
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Clinical practice reveals that therapy with angiogenesis inhibitors often does not prolong survival of cancer patients for more than months, because tumors elicit evasive resistance. In this issue of Cancer Cell, two papers report that VEGF inhibitors reduce primary tumor growth but promote tumor invasiveness and metastasis. These perplexing findings help to explain resistance to these drugs but raise pertinent questions of how to best treat cancer patients with antiangiogenic medicine in the future. We discuss here how VEGF inhibitors can induce such divergent effects on primary tumor growth and metastasis.
引用
收藏
页码:167 / 170
页数:4
相关论文
共 35 条
[11]   Anti-PIGF inhibits growth of VEGF(R)-Inhibitor-Resistant tumors without affecting healthy vessels [J].
Fischer, Christian ;
Jonckx, Bart ;
Mazzone, Massimiliano ;
Zacchigna, Serena ;
Loges, Sonja ;
Pattarini, Lucia ;
Chorianopoulos, Emmanuel ;
Liesenborghs, Laurens ;
Koch, Marta ;
De Mol, Maria ;
Autiero, Monica ;
Wyns, Sabine ;
Plaisance, Stephane ;
Moons, Lieve ;
van Rooijen, Nico ;
Giacca, Mauro ;
Stassen, Jean-Marie ;
Dewerchin, Mieke ;
Collen, Desire ;
Carmeliet, Peter .
CELL, 2007, 131 (03) :463-475
[12]  
FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182
[13]   Long-term progression and therapeutic response of visceral metastatic disease non-invasively monitored in mouse urine using β-human choriogonadotropin secreting tumor cell lines [J].
Francia, Giulio ;
Emmenegger, Urban ;
Lee, Christina R. ;
Shaked, Yuval ;
Folkins, Christopher ;
Mossoba, Miriam ;
Medin, Jeffrey A. ;
Man, Shan ;
Zhu, Zhenping ;
Witte, Larry ;
Kerbel, Robert S. .
MOLECULAR CANCER THERAPEUTICS, 2008, 7 (10) :3452-3459
[14]   Bevacizumab Beyond First Progression Is Associated With Prolonged Overall Survival in Metastatic Colorectal Cancer: Results From a Large Observational Cohort Study (BRiTE) [J].
Grothey, Axel ;
Sugrue, Mary M. ;
Purdie, David M. ;
Dong, Wei ;
Sargent, Daniel ;
Hedrick, Eric ;
Kozloff, Mark .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (33) :5326-5334
[15]   VEGF-induced adult neovascularization: Recruitment, retention, and role of accessory cells [J].
Grunewald, M ;
Avraham, I ;
Dor, Y ;
Bachar-Lustig, E ;
Itin, A ;
Yung, S ;
Chimenti, S ;
Landsman, L ;
Abramovitch, R ;
Keshet, E .
CELL, 2006, 124 (01) :175-189
[16]   Cancer metastasis:: Building a framework [J].
Gupta, Gaorav P. ;
Massague, Joan .
CELL, 2006, 127 (04) :679-695
[17]   Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer [J].
Hurwitz, H ;
Fehrenbacher, L ;
Novotny, W ;
Cartwright, T ;
Hainsworth, J ;
Heim, W ;
Berlin, J ;
Baron, A ;
Griffing, S ;
Holmgren, E ;
Ferrara, N ;
Fyfe, G ;
Rogers, B ;
Ross, R ;
Kabbinavar, F .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (23) :2335-2342
[18]   Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy [J].
Jain, RK .
SCIENCE, 2005, 307 (5706) :58-62
[19]   VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche [J].
Kaplan, RN ;
Riba, RD ;
Zacharoulis, S ;
Bramley, AH ;
Vincent, L ;
Costa, C ;
MacDonald, DD ;
Jin, DK ;
Shido, K ;
Kerns, SA ;
Zhu, ZP ;
Hicklin, D ;
Wu, Y ;
Port, JL ;
Altorki, N ;
Port, ER ;
Ruggero, D ;
Shmelkov, SV ;
Jensen, KK ;
Rafii, S ;
Lyden, D .
NATURE, 2005, 438 (7069) :820-827
[20]   Molecular origins of cancer: Tumor angiogenesis [J].
Kerbel, Robert S. .
NEW ENGLAND JOURNAL OF MEDICINE, 2008, 358 (19) :2039-2049